Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17211807 | 0.87 | ALDH1A1 (0.33) | ALDH1A1GAAMAPTDGAT1 | |
| SCHEMBL17211817 | 0.76 | DGAT1 (0.35) | ALDH1A1GAAMAPTDGAT1AOC3 | |
| SCHEMBL14062046 | 0.76 | DGAT1 (0.46) | DGAT1 | |
| SCHEMBL17211811 | 0.75 | ALDH1A1 (0.31) | ALDH1A1GAAMAPTDGAT1SMN1; SMN2 | |
| SCHEMBL17211812 | 0.72 | — | — | |
| SCHEMBL14061881 | 0.71 | ALDH1A1 (0.43) | ALDH1A1MAPTDGAT1SMN1; SMN2 | |
| SCHEMBL17211799 | 0.70 | MAPT (0.31) | ALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL19443188 | 0.67 | MAPK14 (0.34) | ALDH1A1GAAMAPTDGAT1AOC3 | |
| SCHEMBL18746440 | 0.66 | DGAT1 (0.40) | DGAT1AOC3MAPK14 | |
| SCHEMBL17211809 | 0.66 | ALDH1A1 (0.31) | ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | DGAT1, DGAT2, LCAT | ALDH1A1 945/4885GAA 452/4885MAPT 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.